 | Up a level |
Jump to: 2017
Number of items: 1.
2017
Chowdhury, S., Abida, W., Arranz Arija, J., Daugaard, G., Fizazi, K., Gez, E., Heidenreich, A., Joly Lobbedez, F., McDermott, R., Merseburger, A. S., Piulats Rodriguez, J. M., Sautois, B., Sridhar, S., Sternberg, C. N., Watkins, S., Simmons, A., Shetty, S., Golsorkhi, A., Ryan, C. J. and Scher, H. (2017). The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041